Skip to main content
Meds CJC-1295

A clear, browsable digest of the CJC-1295 research literature — every pharmacokinetic study, the DAC vs no-DAC distinction, and where the human data actually stand, laid out like a well-organized listing.

Amounts tested in people and mice

What CJC-1295 dosage did researchers test?

You can see the study amounts used on people and mice. They don't set a personal dose, and CJC-1295 has no approved human dose.

What amounts did the studies use?

Each person in the human studies received one dose beneath the skin: 30, 60, or 90 micrograms per kilogram of the person's weight [1][3]. A mouse study used 2 micrograms at 24-, 48-, or 72-hour gaps. Growth returned to normal when the mice got the drug once a day [4].

Those are research amounts, not personal doses. Online plans for the short form and for CJC-1295 with ipamorelin often name 100-300 micrograms for everyone. No fair study with comparison groups set those plans [1]. CJC-1295 has never been approved as human care, so there is no set treatment dose [1].

The figures show what the studies tested, but they don't plan a shot for you.

Did larger amounts cause larger blood-test changes?

Yes. Larger CJC-1295 amounts caused larger and longer blood-test changes. Healthy adults received 30 or 60 micrograms for every kilogram they weighed. With the smaller shot, growth hormone reached 2 times its starting level; the larger shot raised it ten times. Both changes were still present on the sixth day. Insulin-like growth factor, called IGF-1, stayed high for 9 to 11 days [1]. Another study used 60 or 90 micrograms per kilogram in healthy men. One week later, their average growth-hormone level was about 46% higher [3].

Time between doses also mattered in mice. They received 2 micrograms every 24 hours. Their weight and length returned to normal, while the same amount every 48 or 72 hours worked less well [4].

These figures show what changed in those studies [1][3][4], but they can't name a safe amount for you.

Did larger amounts cause larger blood-test changes?

Why don't online plans match the studies?

Study amounts and online plans come from different places. Researchers based the human amounts on body weight because they wanted to learn how long the drug remained in blood [1][3]. Online plans often give one fixed amount to everyone. Plans for the short form and the CJC-1295/ipamorelin pair often name 100-300 micrograms. No fair study on people created those plans [1].

Researchers pair the two drugs because they start hormone release in different ways. That gives them a reason to test the pair, not a tested human dose [11]. CJC-1295 has no approved use. Public agencies have set no dose for either form [1].

Study amounts show what researchers tested; they don't become a care plan for you.

How did labs give and keep the drug?

Researchers usually put CJC-1295 beneath the skin, while earlier work put the body's short growth-hormone message into a vein [9]. Swallowing gives the body almost none because the stomach breaks this kind of drug apart [1].

For study use, researchers mixed the dry powder with water that slows germ growth and kept it cold [1]. Four changed protein parts slow its breakdown. In the DAC form, an added link lets albumin carry the drug across several days [2][8]. Those facts explain the studies, but they don't give you home-mixing or dose directions. Your doctor can answer what a safe next step is.

Can these studies set a CJC-1295 dose for you?

No. In human studies, each person received one shot beneath the skin of 30, 60, or 90 micrograms per kilogram. CJC-1295 isn't approved, so it has no set human treatment dose [1][3]. Those amounts helped researchers track the drug. They weren't a care plan.

No public agency has set a CJC-1295 dose for any illness [1]. The studies can't answer your personal dose question.

These CJC-1295 figures cannot become a care plan: mypromise.com describes the prescription care at Promise Peptides, where CJC-1295 is prescribed today if a licensed U.S. clinician finds it appropriate after reading the case. The clinician can also turn a request down. The service takes patients in the U.S. only; its options differ from one state to another and from one treatment to another. The compounded medicine has no FDA approval.

Did a trial set a CJC-1295 / ipamorelin dose?

No fair study on people set a dose for the CJC-1295/ipamorelin pair. Researchers test the pair because each drug starts growth-hormone release in a different way. Online fixed-dose plans didn't come from trials [11].

Those two ways support more study, but they don't prove a dose is safe or useful. The published work gives you no tested human amount [11].

Do studies give CJC-1295 home-mixing directions?

No. The studies say labs add water that holds back germ growth to the dry drug, then keep it cold. Swallowing gives the body almost none because stomach juices break this kind of drug apart [1].

That is a note about lab work, not a home-mixing guide. Four changed protein parts protect the drug from cutting by blood enzymes [8]. That lab note doesn't tell you how to mix the drug at home.

Did a study choose a CJC-1295 shot spot for you?

No. The studies name no body part. Researchers put the drug beneath the skin, while earlier work used a vein for the body's short message [9]. Those details tell you how the drug was given.

Blood changes lasting several days followed shots beneath the skin [1], but the papers give no spot for your own shot.